Medical use of cannabis for patients with end stage kidney disease
CLU: 2.0

Hypoxia-inducible factor (HIF) stabilizers: An emerging treatment option for anemia in chronic kidney disease
CLU: 2.0

Health Disparities and Outcomes in Canadian Indigenous End-Stage Kidney Disease Patients
CLU 2.0

Potassium Binding Agents:  Patiromer and Sodium Zirconium Cycloscilicate
CLU 2.0

Prevention and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease
CLU 2.0

Prophylactic management of contrast-induced acute kidney injury in high-risk patients
CLU 2.0

The role of Direct Oral Anticoagulant (DOACs) in Hemodialysis
CLU 2.0

An introduction to chemotherapy-associated nephrotoxicity
CLU 3.0

An introduction to chemotherapy-associated nephrotoxicity

Warfarin for stroke prevention in hemodialysis patients with non-valvular atrial fibrillation

Management of pain in patients on hemodialysis
CLU 2.0

Restless Legs Syndrome (RLS) in hemodialysis patients
CLU 2.0

Uremic pruritis
CLU 2.0

Over-the-Counter Drugs to Avoid in Older Adults with Kidney Impairment
CLU 2.0

Sodium glucose cotransporter 2 (SGLT2) inhibitors—Their role in the kidneys
CLU 2.0

Antimicrobial stewardship: Is there a role in hemodialysis?
CLU 2.0

Acute kidney injury secondary to lymphoma
CLU 2.0

Drug dosing in dialysis
CLU 2.0

Low molecular weight heparin for the treatment of deep vein thrombosis and pulmonary embolism in patients with chronic kidney disease
CLU 2.0